{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:33:12Z","timestamp":1791592392204,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.neulet.2018.05.052","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T12:49:00Z","timestamp":1528289340000},"page":"100-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Effect of montelukast in experimental model of Parkinson\u2019s disease"],"prefix":"10.1016","volume":"682","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1875-7258","authenticated-orcid":false,"given":"Vetrivel Babu","family":"Nagarajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmaja Anil","family":"Marathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2018.05.052_bib0005","doi-asserted-by":"crossref","DOI":"10.1176\/jnp.14.2.223","article-title":"An essay on the shaking palsy","volume":"14","author":"Parkinson","year":"2002","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.neulet.2018.05.052_bib0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/978-94-007-5416-4_16","article-title":"Parkinson\u2019s disease","volume":"65","author":"Mhyre","year":"2012","journal-title":"Subcell. Biochem."},{"key":"10.1016\/j.neulet.2018.05.052_bib0015","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson\u2019s disease: risk factors and prevention","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neulet.2018.05.052_bib0020","unstructured":"Parkinson\u2019s Foundation: Better Lives. Together., (n.d.). http:\/\/parkinson.org\/Understanding-Parkinsons\/Causes-and-Statistics\/Statistics.(Accessed 29 January 2018)."},{"key":"10.1016\/j.neulet.2018.05.052_bib0025","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4103\/2231-0738.114849","article-title":"Parkinson\u2032s disease in India: an analysis of publications output during 2002- 2011","volume":"3","author":"Bala","year":"2013","journal-title":"Int. J. Nutr. Pharmacol. Neurol. Dis."},{"key":"10.1016\/j.neulet.2018.05.052_bib0030","series-title":"Harrison\u2019s Principles of Internal Medicine","first-page":"2609","article-title":"Parkinson\u2019s disease and other movement disorders","author":"Olanow","year":"2015"},{"key":"10.1016\/j.neulet.2018.05.052_bib0035","first-page":"504","article-title":"Parkinson\u2019s disease and its management: part 1: disease entity, risk factors, pathophysiology","volume":"40","author":"DeMaagd","year":"2015","journal-title":"Clin. Present. Diagnosis P T"},{"key":"10.1016\/j.neulet.2018.05.052_bib0040","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1590\/S0104-11692012000200023","article-title":"Quality of life of a person with Parkinson\u2019s disease and the relationship between the time of evolution and the severity of the disease","volume":"20","author":"Navarro-Peternella","year":"2012","journal-title":"Rev. Lat. Am. Enfermagem."},{"key":"10.1016\/j.neulet.2018.05.052_bib0045","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of parkinson disease","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.neulet.2018.05.052_bib0050","series-title":"Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics","first-page":"609","article-title":"Treatment of central nervous system degenerative disorders","author":"Standeart","year":"2012"},{"key":"10.1016\/j.neulet.2018.05.052_bib0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.brainres.2014.05.026","article-title":"Regulation of rotenone-induced microglial activation by 5-lipoxygenase and cysteinyl leukotriene receptor 1","volume":"1572","author":"Zhang","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.neulet.2018.05.052_bib0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11064-014-1478-9","article-title":"Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats","volume":"40","author":"Saad","year":"2015","journal-title":"Neurochem. Res."},{"issue":"8466","key":"10.1016\/j.neulet.2018.05.052_bib0065","article-title":"Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug","volume":"6","author":"Marschallinger","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neulet.2018.05.052_bib0070","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.neuroscience.2010.08.039","article-title":"Protective effect of montelukast against quinolinic acid\/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-\u03b1 level alterations in rats","volume":"171","author":"Kalonia","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neulet.2018.05.052_bib0075","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1734-1140(12)70905-2","article-title":"Characterization of motor, depressive-like and neurochemical alterations induced by a short-term rotenone administration","volume":"64","author":"Morais","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neulet.2018.05.052_bib0080","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jnc.13087","article-title":"Neuroprotective effects of vildagliptin in rat rotenone Parkinson\u2019s disease model: role of RAGE-NF\u03baB and Nrf2-antioxidant signaling pathways","volume":"133","author":"Abdelsalam","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2018.05.052_bib0085","doi-asserted-by":"crossref","first-page":"214","DOI":"10.5607\/en.2013.22.3.214","article-title":"Beneficial effect of vitamin e in rotenone induced model of PD: behavioural, neurochemical and biochemical study","volume":"22","author":"Sharma","year":"2013","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.neulet.2018.05.052_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/401264","article-title":"Oxidative stress and microglial cells in parkinson\u2019s disease","volume":"2012","author":"Peterson","year":"2012","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.neulet.2018.05.052_bib0095","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.neuint.2012.12.016","article-title":"Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson\u2019s disease","volume":"62","author":"Taylor","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neulet.2018.05.052_bib0100","series-title":"Evaluation of Drug Activities Pharmacometrics","author":"Paget","year":"1964"},{"key":"10.1016\/j.neulet.2018.05.052_bib0105","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/cns.12596","article-title":"Cysteinyl leukotrienes and their receptors: emerging therapeutic targets in central nervous system disorders","volume":"22","author":"Ghosh","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neulet.2018.05.052_bib0110","first-page":"150","article-title":"5-lipoxygenase is involved in rotenone-induced injury in PC12 cells","volume":"40","author":"Zhang","year":"2011","journal-title":"Zhejiang Da Xue Xue Bao. Yi Xue Ban."},{"key":"10.1016\/j.neulet.2018.05.052_bib0115","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.neuropharm.2013.06.014","article-title":"Protection of dopaminergic neurons by 5-lipoxygenase inhibitor","volume":"73","author":"Kang","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neulet.2018.05.052_bib0120","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1100\/tsw.2010.229","article-title":"Montelukast: more than a cysteinyl leukotriene receptor antagonist","volume":"10","author":"Tintinger","year":"2010","journal-title":"Sci. World J."},{"key":"10.1016\/j.neulet.2018.05.052_bib0125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jsps.2011.06.002","article-title":"Effects of Montelukast on free radical production in whole blood and isolated human polymorphonuclear neutrophils (PMNs) in asthmatic children","volume":"19","author":"Al Saadi","year":"2011","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.neulet.2018.05.052_bib0130","first-page":"1770","article-title":"Effects of montelukast and methylprednisolone on experimental spinal cord injury in rats","volume":"18","author":"Cavus","year":"2014","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.neulet.2018.05.052_bib0135","doi-asserted-by":"crossref","first-page":"869","DOI":"10.12659\/MSM.892932","article-title":"Montelukast inhibits pentylenetetrazol-induced seizures in rats","volume":"21","author":"Cevik","year":"2015","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.neulet.2018.05.052_bib0140","doi-asserted-by":"crossref","first-page":"e20677","DOI":"10.1371\/journal.pone.0020677","article-title":"Edaravone guards dopamine neurons in a rotenone model for parkinson\u2019s disease","volume":"6","author":"Xiong","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neulet.2018.05.052_bib0145","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/WNR.0000000000000740","article-title":"Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model ofParkinson\u2019s disease","volume":"28","author":"Jang","year":"2017","journal-title":"Neuroreport"}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394018304038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394018304038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T20:22:58Z","timestamp":1759609378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394018304038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":29,"alternative-id":["S0304394018304038"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2018.05.052","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of montelukast in experimental model of Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2018.05.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}